A Dose-Finding Trial for Hyperthermic Intraperitoneal Cisplatin in Gynecological Cancer Patients Receiving Hyperthermic Intraperitoneal Chemotherapy.

Chan, Chui-Ying; Li, Hui; Wu, Miao-Fang; Liu, Chang-Hao; Lu, Huai-Wu; Lin, Zhong-Qiu; Li, Jing

Chan, Chui-Ying; Li, Hui; Wu, Miao-Fang; Liu, Chang-Hao; Lu, Huai-Wu; Lin, Zhong-Qiu; Li, Jing.

Afiliación

Chan CY; Department of Gynecologic Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Li H; Department of Gynecologic Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Wu MF; Department of Gynecologic Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Liu CH; Department of Gynecologic Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Lu HW; Department of Gynecologic Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Lin ZQ; Department of Gynecologic Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Li J; Department of Gynecologic Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.

Front Oncol ; 11: 616264, 2021.

Article en En | MEDLINE | ID: mdl-33777754

Palabras clave

Bayesian optimal interval design; cisplatin; dose-finding trial; gynecological cancer; hyperthermic intraperitoneal chemotherapy; kidney injury; maximum tolerated dose

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Front Oncol Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google